ruxolitinib

small molecule (kinase inhibitor)

12.1 Mechanism of Action Ruxolitinib, a Janus kinase (JAK) inhibitor, inhibits JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization of STATs to the nucleus leading to modulation of gene expression. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

Tyrosine-protein kinase JAK2, Tyrosine-protein kinase JAK1, Tyrosine-protein kinase JAK3, Non-receptor tyrosine-protein kinase TYK2, Urokinase plasminogen activator surface receptor

—

atopic dermatitis — FDA · vitiligo — FDA

atopic dermatitis, alopecia areata, vitiligo, hidradenitis suppurativa

max 20% BSA / 60 g per week (topical formulation)

2026-04-19